Market cap
$224 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
11.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-89.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.8
-
Face value
--
-
Shares outstanding
14,788,400
10 Years Aggregate
CFO
$-561.40 Mln
EBITDA
$-481.95 Mln
Net Profit
$19.06 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Merrimack Pharmaceuticals (MACK)
| 12.8 | 2.7 | 2.9 | 21.0 | 33.5 | 28.3 | -6.9 |
|
BSE Sensex*
| -8.9 | 2.5 | 2.2 | -5.7 | 6.8 | 8.0 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Merrimack Pharmaceuticals (MACK)
| 17.0 | 193.1 | -43.3 | 118.7 | 16.7 | -62.1 | -54.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Merrimack Pharmaceuticals (MACK)
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
-
President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
Mr. Gary L. Crocker M.B.A.
-
President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
Mr. Gary L. Crocker M.B.A.
-
Headquarters
Cambridge, MA
-
Website
FAQs for Merrimack Pharmaceuticals (MACK)
What is the current share price of Merrimack Pharmaceuticals Inc (MACK) Today?
The share price of Merrimack Pharmaceuticals Inc (MACK) is $15.13 (NASDAQ) as of 28-May-2024 09:30 EDT. Merrimack Pharmaceuticals Inc (MACK) has given a return of 33.49% in the last 3 years.
What is the current PB & PE ratio of Merrimack Pharmaceuticals Inc (MACK)?
Since, TTM earnings of Merrimack Pharmaceuticals Inc (MACK) is negative, P/E ratio is not available.
The P/B ratio of Merrimack Pharmaceuticals Inc (MACK) is 11.38 times as on 28-May-2024, a 175 premium to its peers’ median range of 4.14 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-158.97
|
10.01
|
|
2022
|
-103.91
|
8.34
|
|
2021
|
-20.70
|
3.58
|
|
2020
|
-29.58
|
5.60
|
|
2019
|
-1.93
|
2.37
|
What is the 52 Week High and Low of Merrimack Pharmaceuticals Inc (MACK)?
The 52-week high and low of Merrimack Pharmaceuticals Inc (MACK) are Rs -- and Rs -- as of 18-Jun-2026.
What is the market cap of Merrimack Pharmaceuticals Inc (MACK)?
Merrimack Pharmaceuticals Inc (MACK) has a market capitalisation of $ 224 Mln as on 28-May-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Merrimack Pharmaceuticals Inc (MACK)?
Before investing in Merrimack Pharmaceuticals Inc (MACK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.